Status message

We are currently rebuilding the search index. Some search results may be inaccurate or incomplete.

Using a functional genetic screen for inhibitors of γ-secretase activity, researchers have identified an unusual gene that keeps a lid on both amyloid production and tau phosphorylation in mouse brain. The expressed protein, RPS23R1, activates the cAMP/protein kinase A pathway, which ends in inhibition of glycogen synthase kinase 3 (GSK3), an upstream regulator of Aβ processing and a major tau kinase. Although it is not clear whether the mouse gene has a human homolog, the findings open the possibility that targeting upstream events in the cAMP/PKA/GSK3 pathway might offer an approach to preventing both Aβ and tau pathology with a single drug. The work, from Huaxi Xu of the Burnham Institute for Medical Research in La Jolla, California; Limin Li of Functional Genetics, Inc., Gaithersburg, Maryland, and the Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; and collaborators appears in today’s issue of Neuron.

In the study, the four first authors, Yun-wu Zhang, Shijie Liu, Xue Zhang, and Wu-Bo Li, combined elegant molecular, cell, and animal approaches to define the new pathway. They first undertook a functional screen for genes that decrease Aβ production in mouse cells using retroviral-mediated gene disruption. The insertion vector carries a strong promoter, which can drive transcription when it lands in or near a gene. Insertion downstream of genes results in a knockout phenotype via antisense transcription, while upstream insertion can result in a gene overexpression phenotype. After viral infection, N2a cells that express a mutated human amyloid precursor protein (APPSwe) were screened for γ-secretase inactivation by sorting for cells with increased cell surface expression of APP βCTF (C-terminal fragment, the substrate for γ-secretase).

The researchers focused on one clone that showed a high level of cell surface APP bCTF and a significant decrease in Aβ. They found the changes were due to the activation of a novel mouse gene by the viral insertion. This gene, Rps23r1, was unusual in that it originated by retroposition, a process by which mRNAs reverse transcribe and re-insert into the genome at random, creating new genes. Rps23r1 is a copy of a gene encoding a mouse ribosomal protein, but transcribed in the reverse orientation compared to its parent. That gives rise to a protein of entirely new sequence, and the Rps23r1 product proved to be a transmembrane protein mainly localized to the hippocampus, dentate gyrus, and cortex.

When the researchers overexpressed Rps23r1 in cells, they found it caused inhibition of GSK3α and β, two related kinases upstream of both Aβ production (see ARF related news story on Phiel et al., 2003; Su et al., 2004) and tau phosphorylation. The addition of the GSK3 inhibitor lithium to the cells did not further reduce kinase activity or Aβ production, suggesting that Rps23r1 has its effects via inhibition of GSK3. Tracing the actions of Rps23r1 farther upstream, the authors showed that the protein interacts with adenylate cyclase, boosts cAMP levels, and activates PKA. This results in inhibitory phosphorylation of GSK3, reduced Aβ production, and decreased tau phosphorylation.

To look at Rps23r1 action in vivo, the researchers made a transgenic mouse that overexpressed the protein in brain by twofold over endogenous levels. The mice had decreased GSK3 activity in brain, and increased CREB phosphorylation (an indicator of elevated PKA). When the mice were crossed with triple-transgenic mice expressing human mutated APP, tau, and presenilin 1 (Oddo et al., 2003), their offspring had increased levels of cAMP and PKA activity, and decreased GSK3 activation, tau phosphorylation, and Aβ levels. Levels of the synaptic marker PSD-95 and synapsin were both increased, the authors reported, suggesting that synaptic impairment may be ameliorated in the mice.

Despite their efforts, the researchers were unable to identify a human homolog of the mouse gene, but they did demonstrate that the Rps23r1 could regulate GSK3 and Aβ levels in human cells.

Scott Small of Columbia University, New York, calls the study an “important proof of principle.” Small, who was not involved in the work, told ARF, “Even though the new gene doesn’t clearly exist in humans, the findings do have immediate therapeutic implications because they suggest there could be a single drug that hits both pathologies simultaneously.” The study supports a “dual pathway” hypothesis for AD, as outlined by Small and Karen Duff in a review published last year (Small and Duff, 2008, and a related Live Discussion). The hypothesis suggests that Aβ and tau pathologies are linked through common upstream events, rather than viewing tau perturbation as a sequential consequence of Aβ overproduction (the amyloid hypothesis).

For his part, Xu speculates that the mouse-specific gene might explain the mystery of why mice do not get AD. While there are other possible explanations, the protection afforded by PKA activation and GSK3 inhibition could be a contributing factor. “Our biggest challenge now is to do a knockout,” Xu said. “We want to see if you knockout this gene, will you get Aβ buildup or an AD-type condition in the mice?”

The random targeting approach has yielded other interesting genes as well, which Xu says the group is characterizing now.—Pat McCaffrey.

Reference:
Zhang Y, Liu S, Zhang X, Li W, Chen Y, Huang X, Sun L, Luo W, Netzer WJ, Threadgill R, Wiegand G, Wang R, Cohen SN, Greengard P, Liao F, Li L, Xu H. A functional mouse retroposed gene Rps23r1 reduces Alzheimer's b-amyloid levels and tau phosphorylation. Neuron. 2009 Nov 12; 64:328-340. Abstract

Comments

Make a Comment

To make a comment you must login or register.

Comments on this content

  1. In establishing a link between the Aβ and tau pathologies, Zhang and colleagues used an elegant screening approach called random homozygous gene perturbation (RHGP). It allowed them, in mouse N2a cells, to identify a retrotransposed gene that “interacted” with APP/Aβ by causing increased surface accumulation of APP βCTF. It turned out when transfecting this gene into several different cell lines from a range of species, that this causes an interaction with adenylate cyclases, activating the kinase PKA, which then inactivates GSK3, which, having both tau and APP as substrate, results in reduced tau phosphorylation and Aβ production.

    It is interesting to see that GSK3 is the common denominator and any protein in the PKA/GSK cascade seems to be a suitable drug target. The authors move on to generate an Rps23r1 transgenic mouse strain, which they cross with the triple AD mouse generated by Salvatore Oddo and Frank LaFerla. The authors show that this is beneficial with regard to GSK3 activity, tau phosphorylation, and Aβ formation. Whether humans have a homologue of Rps23r1 is not known, as the authors of the study point out. They speculate what the implications might be “should humans lack Rps23r1 homologues.” It would be interesting to know whether they have found more novel genes in the course of the RHGP screening and, if so, whether these fall into distinct categories.

  2. This manuscript shows the value of functional genetics screens in identifying previously unrecognized modulators of GSK3 function, and emphasizes the centrality of dynamic tau phosphorylation as a key mechanism in AD pathology. When the functional role of this type of novel component is fully understood, it may offer a route toward understanding the basis of therapeutic response as one element. Previous attempts to link GSK3 to both pathologies have been inconclusive since not all GSK3 inhibitors inhibit both Aβ and tau phosphorylation and even if some of them do, there is a clear disconnect between the concentrations needed to reduce Aβ levels, and tau phosphorylation. The identification of Rps23r1 clearly represents an important step in identifying common pathways that regulate both Aβ levels and tau phosphorylation. The authors provide convincing evidence of this in the triple transgenic mouse. Equally important is the fact that this protein exerts its effects in human cells. Although Rsp23r1 itself may not be amenable as a drug discovery approach, negative regulators of this pathway either upstream or downstream may prove to be of value in Alzheimer disease.

Comments on Primary Papers for this Article

No Available Comments on Primary Papers for this Article

References

News Citations

  1. Lithium Hinders Aβ Generation, Buffing Up GSK as Drug Target

Webinar Citations

  1. LOAD and eFAD—Different Diseases, Different Hypotheses?

Paper Citations

  1. . GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature. 2003 May 22;423(6938):435-9. PubMed.
  2. . Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry. 2004 Jun 8;43(22):6899-908. PubMed.
  3. . Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003 Jul 31;39(3):409-21. PubMed.
  4. . Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron. 2008 Nov 26;60(4):534-42. PubMed.
  5. . A functional mouse retroposed gene Rps23r1 reduces Alzheimer's beta-amyloid levels and tau phosphorylation. Neuron. 2009 Nov 12;64(3):328-40. PubMed.

Further Reading

Papers

  1. . A functional mouse retroposed gene Rps23r1 reduces Alzheimer's beta-amyloid levels and tau phosphorylation. Neuron. 2009 Nov 12;64(3):328-40. PubMed.

News

  1. Lithium Hinders Aβ Generation, Buffing Up GSK as Drug Target

Primary Papers

  1. . A functional mouse retroposed gene Rps23r1 reduces Alzheimer's beta-amyloid levels and tau phosphorylation. Neuron. 2009 Nov 12;64(3):328-40. PubMed.